The Medicines Company's anesthetic shows positive results in 1st human trial: 4 things to know

The Medicines Company announced Phase 1 results for ABP-700, a novel, investigational intravenous anesthetic.

Here are four things to know:

1. The first-in-human study included 60 subjects and was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ABP-700.

2. Study results showed linear dose-proportional pharmacokinetics and pharmacodynamic effects, which were rapidly reversible.

3. Adverse events were mild with the exception of one subject with moderate tachycardia. No serious adverse events were reported.

4. The results were presented at the 2015 Annual Dutch Society of Anesthesiology Conference in Maastricht, Netherlands.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast